Combined Use of Radioprotective and Radiosensitizing Drugs in Experimental Radiotherapy

Publisher Website
Google Scholar
Abstract
The application of radioprotective and radiosensitizing drugs in clinical radiotherapy is limited by the large drug doses required to obtain significant therapeutic gains. A potential means of circumventing these toxicity problems, while retaining significant therapeutic gains, would be to use small doses of both types of drugs. This possibility was tested, using the specific drug combination WR-2721 [5-2-(3-aminopropylamino)ethylphosphorothioic acid] and Ro-07-0582 [1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol] with the following results: the 2 drugs are not additive in terms of lethal toxicity in the mouse; WR-2721 does not interfere with the ability of Ro-07-0582 to sensitize tumors in vivo and Ro-07-0582 does not interfere with the ability of WR-2721 to protect mouse skin. While the therapeutic gains depend on the radiation dose and endpoints considered, the combination was superior to either drug alone in all cases. The success of there preliminary investigations would appear to warrant further study.

This publication has 0 references indexed in Scilit: